Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
暂无分享,去创建一个
Jenny C. Chang | W. Qian | R. Rosato | D. Choi | A. Kozielski | H. Wong | Wen Chen | B. Dave | D. Davila-Gonzalez | Wen Chen | H. Wong
[1] M. Socinski,et al. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer , 2018, Molecular Diagnosis & Therapy.
[2] J. Banchereau,et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] Yiling Lu,et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.
[4] B. Levy,et al. Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. , 2017, Annals of translational medicine.
[5] L. Rubinstein,et al. The Challenge for Development of Valuable Immuno-oncology Biomarkers , 2017, Clinical Cancer Research.
[6] L. Emens. Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.
[7] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[8] Donald A. Berry,et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. , 2017 .
[9] Sung-Bae Kim,et al. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. , 2017 .
[10] S. Fox,et al. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. , 2017, Pathology.
[11] G. Botti,et al. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients , 2017, International journal of molecular sciences.
[12] Hans Clevers,et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.
[13] Masafumi Nakamura,et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer , 2017, Oncotarget.
[14] A. Jimeno,et al. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. , 2016, Cancer research.
[15] C. Cohen,et al. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. , 2016, American journal of clinical pathology.
[16] Lajos Pusztai,et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Janice S. Sung,et al. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling , 2016, Clinical Cancer Research.
[18] J. Hipp,et al. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? , 2016, Drugs.
[19] J. Banchereau,et al. Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform. , 2016 .
[20] Donna Neuberg,et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.
[21] F. Marincola,et al. Checkpoint Inhibitors and Their Application in Breast Cancer , 2016, Breast Care.
[22] Carsten Denkert,et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.
[23] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[24] A. Ribas. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.
[25] Xue Han,et al. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.
[26] C. Bult,et al. Abstract LB-050: Patient-derived tumor xenografts in humanized NSG mice: a model to study immune responses in cancer therapy , 2015 .
[27] L. Molinero,et al. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .
[28] E. Compérat,et al. Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors? , 2015, Current Urology Reports.
[29] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[30] A. Jimeno,et al. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer , 2015, Oncogene.
[31] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[32] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[33] Hong Zhao,et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.
[34] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[36] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[37] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[38] Stephen T C Wong,et al. Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1 , 2014, Stem cells.
[39] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Marcus Schmidt,et al. Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice , 2014, mAbs.
[41] P. Sharma,et al. PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.
[42] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[43] Chad A Shaw,et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.
[44] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[45] A. Hauschild,et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Jenny C. Chang,et al. Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.
[47] Ian Krop,et al. Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.
[48] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[49] A. Bardelli,et al. Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.
[50] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[51] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[52] F. Mohr,et al. Ten-year follow up after prospectively randomized evaluation of stentless versus conventional xenograft aortic valve replacement. , 2011, Journal of Heart Valve Disease.
[53] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[54] M. Maio,et al. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. , 2010, Seminars in oncology.
[55] Mark T. W. Ebbert,et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.
[56] P. LoRusso,et al. Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.
[57] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[58] D. Greiner,et al. Creation of “Humanized” Mice to Study Human Immunity , 2008, Current protocols in immunology.
[59] Daniel Birnbaum,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.
[60] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[61] A. Vincent-Salomon,et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.
[62] T. Okazaki,et al. PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.
[63] Guangwu Xu,et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know , 2006, Cell Research.
[64] A. Maier,et al. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.
[65] L. Seymour,et al. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[67] B. Evers,et al. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[69] A. Cesano,et al. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. , 1998, The American journal of pathology.
[70] P. Linsley,et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.
[71] H. Yaziji,et al. PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations. , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[72] D. Greiner,et al. Generation of Immunodeficient Mice Bearing Human Immune Systems by the Engraftment of Hematopoietic Stem Cells. , 2016, Methods in molecular biology.
[73] Christopher B Wilson,et al. Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.